SFA Therapeutics, Inc. applications

SFA Therapeutics will begin a Phase 1b trial of patients suffering from Mild to moderate Psoriasis 3Q2020. The study will be conducted in conjunction with Temple University in Philadelphia, PA. Estimated start date is 1 October, 2020.

SFA Therapeutics novel immunomodualtor, SFA006 is planned for testing in COVID-19 Patients 4th Quarter 2020. The trial will test the compound’s ability to prevent the onset of Cytokine Storm Syndrome (CSS) and progression to Acute Respiratory Distress Syndrome (ARDS) in COVID-19 positive patients. Patients will be dosed and monitored for symptom progression hospitalization and death.